Sangamo Therapeutics, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, today announced that the U.S. Food and Drug ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Piper Jaffray Remains Sidelined on Sangamo Biosciences (SGMO) Following 4Q Report February 28, 2017 12:01 PM Sangamo Therapeutics Receives Rare Pediatric Disease Designation From FDA For SB-318 In Vivo Genome Editing Therapeutic For MPS IFebruary 27, 2017 8:00 AM